Highlights
- •While breast cancer treatment is targeted more on tumor and patient characteristics, a tailored individual approach with early and late cardiosurveillance is not yet implemented in routine care.
- •Newly available cardiac imaging techniques are better suited for the early detection of cardiotoxicity and should be used more often in those patients at highest risk.
- •There is an urgent need for a more tailored patient approach to prevent (early) irreversible cardiac damage by cancer treatment.
Abstract
Newly developed treatment strategies for breast cancer have reduced mortality rates
over the past decades. Patients with breast cancer represent a heterogeneous population.
Differences in the severity of the disease require diverse treatment options. Women
have distinct individual risk patterns for cardiovascular disease that may affect
their susceptibility to cardiotoxicity during therapy. While breast cancer treatment
is targeted more on tumor and patient characteristics, a tailored individual approach
with early and late cardiosurveillance is not yet implemented in routine care. Newly
available cardiac imaging techniques are better suited to the early detection of cardiotoxicity
and should be used more often in those patients at highest risk, as the early intervention
afforded will improve their quality of life and prognosis.
Abbreviations:
ACE (angiotensin converting enzyme inhibitors), AI (aromatase inhibitors), BC (breast cancer), DCIS (ductal carcinoma in situ), CVD (cardiovascular disease), ESC (European society of cardiology), GLS (global longitudinal strain), HFpEF (heart failure with preserved ejection fraction), LV (left ventricular), SERM (selective estrogen receptor modulator), VEGF (vascular endothelial growth factor), VTE (venous thrombotic even)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors.Cancer. 2012; 118: 2270-2276
- Cancer genetics and the cardiotoxicity of the therapeutics.J. Am. Coll. Cardiol. 2013; 61: 267-274
- Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.N. Engl. J. Med. 2003; 348: 1625-1638
- Diabetes mellitus and risk of breast cancer: a meta-analysis.Int. J. Cancer. 2007; 121: 856-862
- Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence.Am. J. Clin. Nutr. 2007; 86: s823-s835
- Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.J. Natl. Cancer Inst. 2007; 99: 365-375
- Early breast cancer therapy and cardiovascular injury.J. Am. Coll. Cardiol. 2007; 50: 1435-1441
- Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.Heart. 2015; 101: 1874-1880
- Long-term cardiovascular mortality after radiotherapy for breast cancer.J. Am. Coll. Cardiol. 2011; 57: 445-452
- Distribution of coronary artery stenosis after radiation for breast cancer.J. Clin. Oncol. 2012; 30: 380-386
- Risk of ischemic heart disease in women after radiotherapy for breast cancer.N. Engl. J. Med. 2013; 368: 987-998
- Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.J. Am. Coll. Cardiol. 2012; 60: 2504-2512
- Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.J. Am. Heart Assoc. 2014; 3: e000472
- Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in left-sided breast irradiation for patients with early-stage or locally advanced breast cancer.Am. J. Clin. Oncol. 2013; 36: 24-30
- Left-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further?.Radiother. Oncol. 2013; 108: 248-253
- Should breathing adapted radiotherapy also be applied for right-sided breast irradiation?.Acta Oncol. 2015; : 1-6
- Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.Circulation. 2012; 126: 2749-2763
- Anthracycline cardiotoxicity: from bench to bedside.J. Clin. Oncol. 2008; 26: 3777-3784
- Trastuzumab induced cardiomyopathy: wider implications for cardio-oncology.Heart. 2013; 99: 599-600
- Cancer drugs and the heart: importance and management.Eur. Heart J. 2013; 34: 1102-1111
- Cardio-Oncology: an update on cardiotoxicity of cancer-related treatment.Circ. Res. 2016; 118: 1008-1020
- Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.Prog. Cardiovasc. Dis. 2007; 49: 330-352
- Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.Circulation. 2015; 131: 1981-1988
- Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.J. Am. Coll. Cardiol. 2014; 63: 809-816
- Myocardial protection during cardiotoxic chemotherapy.Circulation. 2015; 132: 1835-1845
- Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.J. Clin. Oncol. 2010; 28: 3422-3428
- Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.Heart. 2013; 99: 634-639
- The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.Circ. Res. 2010; 106: 35-46
- Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery.Circulation. 2015; 132: 2248-2258
- Cardiotoxicity of systemic agents used in breast cancer.Breast. 2014; 23: 317-328
- Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women.JTH. 2003; 1: 2149-2152
- Use of SERMs for treatment in postmenopausal women.J. Steroid Biochem. Mol. Biol. 2014; 142: 142-154
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: aTLAS, a randomised trial.Lancet. 2013; 381: 805-816
- Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo—meta-analyses on efficacy and adverse events based on randomized clinical trials.Breast. 2016; 26: 106-114
- Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.J. Natl. Cancer Inst. 2011; 103: 1299-1309
- Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.Breast Cancer Res. Treat. 2015; 154: 609-616
- The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer.Anticancer Res. 2015; 35: 1559-1566
- Safety of aromatase inhibitor therapy in breast cancer.Expert Opin. Drug Saf. 2015; 14: 1201-1211
- Adverse effects of anticancer agents that target the VEGF pathway.Nat. Rev. Clin. Oncol. 2009; 6: 465-477
- Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control.Int. J. Epidemiol. 2014; 43: 116-128
- The influence of menopause on blood pressure.J. Hum. Hypertens. 1989; 3: 427-433
- Impact of high-normal blood pressure on the risk of cardiovascular disease.N. Engl. J. Med. 2001; 345: 1291-1297
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.Eur. Heart J. 2012; 33: 1787-1847
- How to monitor cardiac toxicity of chemotherapy: time is muscle!.Heart. 2014; 100: 1208-1217
- Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.J. Am. Coll. Cardiol. 2013; 61: 77-84
- Improved interobserver variability and accuracy of echocardiographic visual left ventricular ejection fraction assessment through a self-directed learning program using cardiac magnetic resonance images.J. Am. Soc. Echocardiogr. 2013; 26: 1267-1273
- Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.J. Clin. Oncol. 2010; 28: 3429-3436
- Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy.Int. J. Radiat. Oncol. Biol. Phys. 2013; 85: 1172-1178
- Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking.Cardiovasc. Ultrasound. 2007; 5: 27
- Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Eur. heart J. Cardiovasc. Imaging. 2014; 15: 1063-1093
- Endogenous contrast MRI of cardiac fibrosis: beyond late gadolinium enhancement.JMRI. 2015; 41: 1181-1189
- Single Breath-Hold T1rho-Mapping of the heart for endogenous assessment of myocardial fibrosis.Invest. Radiol. 2016;
- Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.J. Am. Coll. Cardiol. 2010; 55: 213-220
- Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.Eur. Heart J. 2016; (pii: Epub ahead of print): ehw022
Article info
Publication history
Published online: April 23, 2016
Accepted:
April 18,
2016
Received in revised form:
April 11,
2016
Received:
April 8,
2016
Identification
Copyright
© 2016 Elsevier Ireland Ltd. All rights reserved.
